T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherapy combinations are, is currently unknown. We ident...

詳細記述

書誌詳細

主要な著者:	Marta Canel, David Taggart, Andrew H Sims, David W Lonergan, Irene C Waizenegger, Alan Serrels
フォーマット:	Artigo
言語:	Inglês
出版事項:	eLife Sciences Publications Ltd 2020-01-01
シリーズ:	eLife
主題:	FAK immunotherapy cancer T-cell costimulation
オンライン･アクセス:	https://elifesciences.org/articles/48092
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!